- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03665740
Multimodal Investigation of the Neuroprotective Effects of Resveratrol (MINER) (MINER)
A Pilot RCT on the Effect of Resveratrol on Mood, Memory Deficits, Hippocampal Inflammation and Neurogenesis in Veterans With Gulf War Illness
Study Overview
Detailed Description
A randomized controlled trial is proposed that will employ well-validated instruments and state-of-the-art techniques to assess improvements in cognitive functioning, functional status, mood, hippocampal neurogenesis and functional connectivity as well as anti-inflammatory and antioxidant effects of treatment with resveratrol. Design: The proposed study will be an intent-to-treat outpatient, randomized, double-blind, clinical trial of 93 Veterans who meet the Centers for Disease Control and Prevention and Kansas case definitions for GWI.
The study involves a comparison of resveratrol at a dose of 2000 mg and placebo. All doses will be administered orally once or twice daily. Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment. Morning dosing will be taken with or before breakfast. Evening dosing will be taken with or before dinner.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tabitha Alverio, M.A.
- Phone Number: 254.297.3259
- Email: Tabitha.Alverio@va.gov
Study Contact Backup
- Name: Laura Constable, M.A.
- Phone Number: 254.297.3954
- Email: Laura.Constable@va.gov
Study Locations
-
-
Texas
-
Waco, Texas, United States, 76711
- Recruiting
- VISN 17 Center of Excellence for Research on Returning War Veterans
-
Contact:
- Tabitha Alverio, M.A.
- Phone Number: 254-297-3259
- Email: Tabitha.Alverio@va.gov
-
Contact:
- Laura Constable, Ph.D.
- Phone Number: 254.297.3954
- Email: Laura.Constable@va.gov
-
Principal Investigator:
- Dena Davidson, Ph.D.
-
Sub-Investigator:
- Bryann DeBeer, Ph.D.
-
Sub-Investigator:
- Geoffrey May, MD
-
Sub-Investigator:
- Steven Nelson, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Served on active military duty and deployed to the Persian Gulf region August 1990 - July 1991;
- English speaking and able to understand the consent form and study questionnaires;
- Willing and able to be randomized to treatment and to commit to a 26-week study;
- Men and women between the ages of 44 to 68 (the number of 1990-1991 Gulf War Veterans who are older than 68 dramatically decreases because many of those with GWI have died prematurely);
- Meet the Kansas case definition for the diagnosis of GWI as well as the more inclusive CDC definition
- Stabilization on any psychiatric medication (≥3 months on selective serotonin reuptake inhibitor or monoamine oxidase inhibitor, ≥1 month on anxiolytic or beta-blockers);
- Female subjects of childbearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test and agree to use reliable method of birth control (for example, oral contraceptives or Norplant; a reliable barrier method of birth control [diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam]; intrauterine devices; partner with vasectomy; or abstinence) during the study. Note that this inclusion criterion applies only to females of childbearing potential. Females of childbearing potential are defined as women not surgically sterilized and between menarche and 2 years post-menopause.
Exclusion Criteria:
- Unstable or poorly controlled diabetes type II (HbA1C >9.0);
- Cancer;
- Lifetime diagnosis of schizophrenia or bipolar disorder or a history of psychiatric hospitalization for, or current diagnosis (i.e., the past 6 months) of substance dependence;
- Major depressive disorder or posttraumatic stress disorder requiring hospitalization;
- Significant CNS disease including TIAs or stroke, dementia, syncopal episodes, severe head trauma, multiple sclerosis;
- Serious or advanced heart disease or clinically relevant abnormal electrocardiogram (ECG) or postural hypotension;
- Untreated sleep apnea or body mass index (BMI) placing patients at risk for undiagnosed sleep apnea (BMI≥35 kg/m2);
- Subjects with renal insufficiency or chronic renal disease defined by national Kidney Foundation Disease Outcome Quality Initiative criteria (2000) with a GFR less than or equal to 90 mL/min/1.73m2. Laboratory monitoring of CR and Bun and eGFR will be obtained at baseline and prior to each titration and at study end or early termination. If Cr and Bun increase above upper limit of normal and eGFR drops to <45 or more than 35% the study drug will be discontinued and a nephrology consult will be ordered;
- Liver enzymes >3 times normal on 3 consecutive laboratory tests; evidence of significant hepatocellular injury as evidenced by elevated serum levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN); total or indirect bilirubin greater than 1.2 x ULN; alkaline phosphatase greater than 1.5 x ULN; prothrombin time (PT) as INR greater than 2.4 x ULN; or albumin less than 1 times the lower limit of normal (LLN) at baseline. Resveratrol is only anticipated to affect LFTs indirectly, by slowing statin metabolism. Persistent significant elevation of amino transferases are defined as >3x normal of normal upper limit on 2 consecutive measurements. Under the conditions of high dose statin therapy, it is typically addressed by temporarily stopping statin administration, then slowly titrating the dose back up under careful observation. Failure to reduce aminotransferase levels after the temporary cessation of statins (and a third LFT measurement is taken) would necessitate cessation of resveratrol treatment.
- Use of cytochrome P450 3A4 substrates with high risk of toxicity (e.g., terfenadine, cisapride, astemizole, disopyramide, amiodarone, dronedarone, colchicine, cyclosporine, quinidine, pimozide, cisapride, amlodipine, felodipine, nicardipine, nifedipine, nisoldipine, nitrendipin, nimodipine and verapamil);
- Use of blood thinners (e.g., Coumadin);
Use of resveratrol-containing supplements.
Participation in the scanning portion of the study is not required to participate in the clinical trial. Subjects who are interested in the scanning study will be asked to sign a second consent and will be screened for MRI-specific exclusion criteria. The additional exclusion criteria for participating in the MRI portion are listed below.
- General medical conditions that would prevent the participant from completing MRI scanning (active seizure disorder, dementia, active back or muscle spasms);
- Positive MRI safety screen for metal or history of penetrating head or eye wound without subsequent radiological evidence that the wound is metal-free;
- Participants that are (were) welders or that have had metal surgically removed from their eyes without radiological evidence that the wound is metal-free;
- MRI quality problems (tremors, significant claustrophobia);
- Shrapnel or other metal embedded in the body;
- Implanted orthopedic devices (e.g., metal rods, plates or screws but excluding nonferrous material);
- Implanted metal devices or prosthetics, or mechanical implants (e.g., pacemakers, electrical implants, cochlear implants);
- Implanted contraceptive devices (excluding those made of nonferrous material);
- Outside devices made of metal (e.g., neck braces, surgical staples, or artificial limbs), or non-removable dentures, braces or other metal orthodontics;
- Tattoos not done professionally or non-removable body piercings.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Resveratrol
Doses of resveratrol at 500 mg will begin with a dose titration period.
In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
|
resveratrol is an OTC supplement
|
Placebo Comparator: Placebo
Doses of placebo at 500 mg will begin with a dose titration period.
In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
|
resveratrol is an OTC supplement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Cognitive Function
Time Frame: Baseline & Post (week 26)
|
CVLT-II: measure of cognitive functioning and memory
|
Baseline & Post (week 26)
|
Change from baseline in Mood
Time Frame: Baseline, Mid (week 13) and Post (week 26)
|
Beck Depression Inventory II
|
Baseline, Mid (week 13) and Post (week 26)
|
Change from baseline in Daily Functioning
Time Frame: Baseline and Post (week 26)
|
WHODAS 2.0: measure of disability and global health
|
Baseline and Post (week 26)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Structural MRI Scans
Time Frame: Baseline & Post (Week 26)
|
Structural MRI scanning of hippocampus
|
Baseline & Post (Week 26)
|
Change from baseline in Diffusion Tensor Imaging
Time Frame: Baseline & Post (Week 26)
|
A diffusion tensor imaging scan of hippocampus
|
Baseline & Post (Week 26)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in Pro-inflammatory cytokines
Time Frame: Baseline & Post (Week 26)
|
IL-1β; TNF-α; IL-6; IL-1α; Interferon-Y; G-CSF/CSF3; GM_CSF/CSF2; IL-8; IP-10; RANTES; Resistin; PAI-1; IL-12; IL-13; Eotaxin-3; MCP-1; MIP-1α; IL-2; Leptin; Adiponectin; IL-17α; IL-4; IL10
|
Baseline & Post (Week 26)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dena Davidson, Ph.D., VISN 17 Center of Excellence
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GW160050
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gulf War Illness
-
National Institute of Neurological Disorders and...RecruitingGulf War IllnessUnited States
-
East Carolina UniversityCompletedGulf War IllnessUnited States
-
K-PAX Pharmaceuticals, Inc.VA Palo Alto Health Care SystemUnknownGulf War IllnessUnited States
-
Nova Southeastern UniversityBoston University; RTI InternationalRecruiting
-
VA Office of Research and DevelopmentTexas A&M UniversityTerminatedGulf War IllnessUnited States
-
Icahn School of Medicine at Mount SinaiUnited States Department of Defense; Department of Veterans Affairs, New JerseyCompletedGulf War IllnessUnited States
-
University at AlbanyUnited States Department of Defense; Women's College Hospital; The Sage Colleges and other collaboratorsCompleted
-
Boston University Charles River CampusUnknownGulf War IllnessUnited States
-
Roskamp Institute Inc.United States Department of DefenseRecruiting
-
Roskamp Institute Inc.United States Department of Defense; Nova Southeastern UniversityRecruiting
Clinical Trials on Resveratrol
-
University at BuffaloKaleida HealthTerminatedObesity | Insulin Resistance | Type 2 DiabetesUnited States
-
Jupiter Orphan Therapeutics Inc.National Institute on Aging (NIA)CompletedPharmacokinetics | Food-drug Interaction | SafetyUnited States
-
MaineHealthAmerican Heart AssociationActive, not recruitingCoronary Artery Disease | Diabetes Mellitus, Type 2United States
-
Bernard FiorettiCompleted
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.Completed
-
Albert Einstein College of MedicineAmerican Diabetes AssociationCompletedImpaired Glucose ToleranceUnited States
-
Federal University of Rio Grande do SulCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Completed
-
University of FloridaCompleted
-
Khoo Teck Puat HospitalNational Medical Research Council (NMRC), SingaporeCompleted
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedCoronary Artery Disease | Blood Pressure | Heart Rate | Autonomic Nervous System DiseaseBrazil